Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty
Primary Purpose
Postoperative Pain
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Q8003 (morphine sulfate and oxycodone hydrochloride)
Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Percocet (oxycodone and acetaminophen)
Sponsored by
About this trial
This is an interventional treatment trial for Postoperative Pain focused on measuring total knee arthroplasty, total hip arthroplasty
Eligibility Criteria
Inclusion Criteria:
- Male of female, at least 18 years of age at time of enrollment.
- If female, be at least one year post-menopausal, surgically sterile or practicing effective contraception, be non-lactating, and if of child-bearing potential, have a negative urine pregnancy test result.
- Have a body mass index (BMI) of 38 kg/m2 or less.
- Have undergone a primary unilateral total knee arthroplasty or total hip arthroplasty performed under standardized general, spinal or epidural anesthesia.
- Have developed moderate to severe pain (a score of 2 or more on the 4 point Likert scale or at least 4 on the 11 point NPRS scale within 6 hours of discontinuing PCA on the morning after surgery).
Exclusion Criteria:
- In the opinion of the Investigator, has a history of pulmonary, cardiovascular (including uncontrolled hypertension), neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that, in the opinion of the Investigator, would jeopardize the patient's well being by participation in this study or is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments.
- Used opiates continuously (including tramadol) for more than ten days in the past year.
- Hypersensitivity or poor tolerance to ibuprofen or short term opioids.
- Currently receiving any medications that are not at a stable dose (the same dose for > 2 months prior to date of surgery).
- Was dosed with another investigational drug within 30 days prior to the Screening Visit or has previously received treatment with Q8003.
- Current therapy with central nervous system depressant medications that might increase the risks of treatment with opioids (other than those used with surgical anesthesia).
- Current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).
- History of abusing licit or illicit drug substances within five (5) years of study entry.
- Has taken drugs known to interact with morphine or oxycodone metabolism, including, but not limited to, phenothiazines, monoamine oxidase inhibitors (MAOI), amphetamines, and muscle relaxants within the 4 weeks prior to the date of surgery.
Sites / Locations
- West Alabama Research, Inc.
- Arizona Research Center
- William Beaumont Hospital
- Research Concepts, Ltd.
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
1
2
3
Arm Description
Q8003, flexible ascending dose
Low dose Q8003
Percocet (oxycodone and acetaminophen)
Outcomes
Primary Outcome Measures
Difference in pain intensity scores from baseline
Secondary Outcome Measures
Safety: adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00818493
Brief Title
Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty
Official Title
An Open-Label Pilot Study of the Analgesic Efficacy and Safety Of Q8003 and of the Conversion From IV Morphine PCA Analgesia to Q8003 or to Percocet® in Patients Who Have Undergone Primary Unilateral Total Knee Arthroplasty or Total Hip Arthroplasty
Study Type
Interventional
2. Study Status
Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
July 2009 (Actual)
Study Completion Date
July 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
QRxPharma Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a Phase 2 3-arm, open label pilot study of the safety and efficacy of Q8003 in patients who have undergone primary unilateral total knee arthroplasty or total hip arthroplasty.
Detailed Description
This Phase 2 study is a 3 arm, open-label pilot study to evaluate:
the analgesic efficacy of a flexible ascending regimen of Q8003 compared to a low dose regimen of Q8003 (3 mg/2 mg and potentially up to 6 mg/ 4mg) and to 1-2 Percocet® 5 mg/325 mg tablets. Study drug will be administered every 4-6 hours over a 48-hour Treatment Period to inpatients with moderate to severe postoperative pain who have undergone primary unilateral total knee arthroplasty or total hip arthroplasty.
for the flexible ascending regimen of Q8003 treatment group, to evaluate the adequacy of the algorithm for conversion of IV PCA morphine to oral morphine equivalent doses of Q8003.
the safety of the flexible ascending regimen of Q8003 administered over a 48-hour Treatment Period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain
Keywords
total knee arthroplasty, total hip arthroplasty
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
44 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Q8003, flexible ascending dose
Arm Title
2
Arm Type
Experimental
Arm Description
Low dose Q8003
Arm Title
3
Arm Type
Active Comparator
Arm Description
Percocet (oxycodone and acetaminophen)
Intervention Type
Drug
Intervention Name(s)
Q8003 (morphine sulfate and oxycodone hydrochloride)
Intervention Description
IR Capsules, ascending flexible dose, every 4 to 6 hours
Intervention Type
Drug
Intervention Name(s)
Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Intervention Description
One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
Intervention Type
Drug
Intervention Name(s)
Percocet (oxycodone and acetaminophen)
Intervention Description
One or two 5mg/325 mg tablets every 4 to 6 hours
Primary Outcome Measure Information:
Title
Difference in pain intensity scores from baseline
Time Frame
48 hours
Secondary Outcome Measure Information:
Title
Safety: adverse events
Time Frame
Throughout the 48 hour period
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male of female, at least 18 years of age at time of enrollment.
If female, be at least one year post-menopausal, surgically sterile or practicing effective contraception, be non-lactating, and if of child-bearing potential, have a negative urine pregnancy test result.
Have a body mass index (BMI) of 38 kg/m2 or less.
Have undergone a primary unilateral total knee arthroplasty or total hip arthroplasty performed under standardized general, spinal or epidural anesthesia.
Have developed moderate to severe pain (a score of 2 or more on the 4 point Likert scale or at least 4 on the 11 point NPRS scale within 6 hours of discontinuing PCA on the morning after surgery).
Exclusion Criteria:
In the opinion of the Investigator, has a history of pulmonary, cardiovascular (including uncontrolled hypertension), neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that, in the opinion of the Investigator, would jeopardize the patient's well being by participation in this study or is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments.
Used opiates continuously (including tramadol) for more than ten days in the past year.
Hypersensitivity or poor tolerance to ibuprofen or short term opioids.
Currently receiving any medications that are not at a stable dose (the same dose for > 2 months prior to date of surgery).
Was dosed with another investigational drug within 30 days prior to the Screening Visit or has previously received treatment with Q8003.
Current therapy with central nervous system depressant medications that might increase the risks of treatment with opioids (other than those used with surgical anesthesia).
Current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).
History of abusing licit or illicit drug substances within five (5) years of study entry.
Has taken drugs known to interact with morphine or oxycodone metabolism, including, but not limited to, phenothiazines, monoamine oxidase inhibitors (MAOI), amphetamines, and muscle relaxants within the 4 weeks prior to the date of surgery.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patricia T. Richards, MD, Ph.D.
Organizational Affiliation
QRxPharma Inc.
Official's Role
Study Director
Facility Information:
Facility Name
West Alabama Research, Inc.
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Facility Name
Arizona Research Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85023
Country
United States
Facility Name
William Beaumont Hospital
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073
Country
United States
Facility Name
Research Concepts, Ltd.
City
Houston
State/Province
Texas
ZIP/Postal Code
77024
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
23545428
Citation
Richards P, Gimbel JS, Minkowitz HS, Kelen R, Stern W. Comparison of the efficacy and safety of dual-opioid treatment with morphine plus oxycodone versus oxycodone/acetaminophen for moderate to severe acute pain after total knee arthroplasty. Clin Ther. 2013 Apr;35(4):498-511. doi: 10.1016/j.clinthera.2013.03.002. Epub 2013 Mar 29.
Results Reference
derived
Learn more about this trial
Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty
We'll reach out to this number within 24 hrs